Coming-of-Age of Antibodies in Cancer Therapeutics

Trends in Pharmacological Sciences

Volumn 37, Issue 12, 2016, Pages 1009-1028

  Ayyar, B Vijayalakshmi ^a   Arora, Sushrut ^a   O'Kennedy, Richard ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

antibody drug conjugates; antibody based therapeutics; bispecific antibodies; cancer therapies; immune checkpoint inhibitors

Indexed keywords

AFM 11; AFM 13; AMG 211; AMG 330; ANTINEOPLASTIC AGENT; BLINATUMOMAB; BRENTUXIMAB VEDOTIN; CATUMAXOMAB; ERTUMAXOMAB; IBRITUMOMAB TIUXETAN; INDIUM 111; IODINE 131; IPILIMUMAB; LY 3164530; MGD 006; MGD 007; MM 111; MM 141; MONOCLONAL ANTIBODY; OMP 305B83; RITUXIMAB; RO 6958688; SOLITOMAB; TOSITUMOMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; VANUCIZUMAB; YTTRIUM 90; ANTIBODY; ANTIBODY CONJUGATE; BISPECIFIC ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANTIBODY ENGINEERING; BREAST CANCER; CANCER THERAPY; COLORECTAL CANCER; CROSS LINKING; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HODGKIN DISEASE; HUMAN; IMMUNOGENICITY; LIVER CELL CARCINOMA; MALIGNANT ASCITES; MELANOMA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STOMACH CANCER; TREND STUDY; ANIMAL; DRUG DESIGN; IMMUNOLOGY; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTIBODIES; ANTIBODIES, BISPECIFIC; ANTINEOPLASTIC AGENTS; DRUG APPROVAL; DRUG DESIGN; HUMANS; IMMUNOCONJUGATES; NEOPLASMS;

EID: 84994473844     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2016.09.005     Document Type: Review

References (94)

1. 1 Pescovitz, M.D., Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am. J. Transplant. 6 (2006), 859–866.
2. 2 Niwa, R., Satoh, M., The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology. J. Pharm. Sci. 104 (2015), 930–941.
3. 3 Kohler, G., Milstein, C., Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 (1975), 495–497.
4. 4 Winter, G., Milstein, C., Man-made antibodies. Nature 349 (1991), 293–299.
5. 5 Perez, P., et al. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature 316 (1985), 354–356.
6. 6 Karpovsky, B., et al. Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies. J. Exp. Med. 160 (1984), 1686–1701.
7. 7 Moores, S.L., et al. A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors. Cancer Res. 76 (2016), 3942–3953.
8. 8 Nisonoff, A., Mandy, W.J., Quantitative estimation of the hybridization of rabbit antibodies. Nature 194 (1962), 355–359.
9. 9 James, N.D., et al. A phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HER2+ advanced prostate cancer. Br. J. Cancer 85 (2001), 152–156.
10. 10 Lindhofer, H., et al. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J. Immunol. 155 (1995), 219–225.
11. 11 Byrne, H., et al. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol. 31 (2013), 621–632.
12. 12 Garber, K., Bispecific antibodies rise again. Nat. Rev. Drug Discov. 13 (2014), 799–801.
13. 13 Spiess, C., et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat. Biotechnol. 31 (2013), 753–758.
14. 14 Schaefer, W., et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc. Natl. Acad. Sci. U.S.A. 108 (2011), 11187–11192.
15. 15 Rossi, E.A., et al. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc. Natl. Acad. Sci. U.S.A. 103 (2006), 6841–6846.
16. 16 Schuurman, J., et al. Opening the door to innovation. MAbs. 6 (2014), 812–819.
17. 17 Wu, C., et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat. Biotechnol. 25 (2007), 1290–1297.
18. 18 Kontermann, R.E., Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs 23 (2009), 93–109.
19. 19 Spiess, C., et al. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol. Immunol. 67 (2015), 95–106.
20. 20 Fan, G., et al. Bispecific antibodies and their applications. J. Hematol. Oncol., 8, 2015, 130.
21. 21 Seimetz, D., et al. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3) as a targeted cancer immunotherapy. Cancer Treat. Rev. 36 (2010), 458–467.
22. 22 Jäger, M., et al. The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. Cancer Res. 69 (2009), 4270–4276.
23. 23 Portell, C.A., et al. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin. Pharmacol. 5:Suppl. 1 (2013), 5–11.
24. 24 Wolf, E., et al. BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discov. Today 10 (2005), 1237–1244.
25. 25 Bargou, R., et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321 (2008), 974–977.
26. 26 Brischwein, K., et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol. Immunol. 43 (2006), 1129–1143.
27. 27 Ribera, J-M., et al. Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia. Oncol. Targets Ther. 8 (2015), 1567–1574.
28. 28 Schlereth, B., et al. T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunol. Immunother. 55 (2006), 503–514.
29. 29 Klinger, M., et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 119 (2012), 6226–6233.
30. 30 Topp, M.S., et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-Lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol. 29 (2011), 2493–2498.
31. 31 Strohl, W.R., Fusion proteins for half-life extension of biologics as a strategy to make biobetters. BioDrugs 29 (2015), 215–239.
32. 32 Stieglmaier, J., et al. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer. Expert Opin. Biol. Ther. 15 (2015), 1093–1099.
33. 33 Thakur, A., Lum, L.G., ‘NextGen’ biologics: bispecific antibodies and emerging clinical results. Expert Opin. Biol. Ther. 16 (2016), 675–688.
34. 34 Aigner, M., et al. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia 27 (2013), 1107–1115.
35. 35 Krupka, C., et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood 123 (2014), 356–365.
36. 36 Herrmann, I., et al. Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells. PLoS ONE, 5, 2010, e13474.
37. 37 Cioffi, M., et al. EpCAM/CD3-bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin. Cancer Res. 18 (2012), 465–474.
38. 38 Peng, L., et al. The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA. PLoS ONE, 7, 2012, e36412.
39. 39 Friedrich, M., et al. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-bispecific bite antibody cross-reactive with non-human primate antigens. Mol. Cancer Ther. 11 (2012), 2664–2673.
40. 40 Hasenhindl, C., et al. Stability assessment on a library scale: a rapid method for the evaluation of the commutability and insertion of residues in C-terminal loops of the CH3 domains of IgG1-Fc. Protein Eng. Des. Sel. 26 (2013), 675–682.
41. 41 Kontermann, R.E., Brinkmann, U., Bispecific antibodies. Drug Discov. Today 20 (2015), 838–847.
42. 42 Sheridan, C., Amgen's bispecific antibody puffs across finish line. Nat. Biotechnol. 33 (2015), 219–221.
43. 43 Goldmacher, V.S., Kovtun, Y.V., Antibody–drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells. Ther. Deliv. 2 (2011), 397–416.
44. 44 Perez, H.L., et al. Antibody–drug conjugates: current status and future directions. Drug Discov. Today 19 (2014), 869–881.
45. 45 Roopenian, D.C., Akilesh, S., FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7 (2007), 715–725.
46. 46 McDonagh, C.F., et al. Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index. Mol. Cancer Ther. 7 (2008), 2913–2923.
47. 47 Hamblett, K.J., et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 10 (2004), 7063–7070.
48. 48 Bender, B., et al. A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody–drug conjugate (ADC) for treatment of metastatic breast cancer. AAPS J. 16 (2014), 994–1008.
49. 49 Lin, K., Tibbitts, J., Pharmacokinetic considerations for antibody drug conjugates. Pharm. Res. 29 (2012), 2354–2366.
50. 50 Stimmel, J.B., et al. Site-specific conjugation on serine → cysteine variant monoclonal antibodies. J. Biol. Chem. 275 (2000), 30445–30450.
51. 51 Junutula, J.R., et al. Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. J. Immunol. Methods 332 (2008), 41–52.
52. 52 Junutula, J.R., et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotech. 26 (2008), 925–932.
53. 53 Mack, F., et al. The next generation of antibody drug conjugates. Semin. Oncol. 41 (2014), 637–652.
54. 54 Younes, A., et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J. Clin. Oncol. 30 (2012), 2776–2782.
55. 55 Alley, S.C., et al. Antibody–drug conjugates: targeted drug delivery for cancer. Curr. Opin. Chem. Biol. 14 (2010), 529–537.
56. 56 Govindan, S.V., Goldenberg, D.M., Designing immunoconjugates for cancer therapy. Expert. Opin. Biol. Ther. 12 (2012), 873–890.
57. 57 Polson, A.G., et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res. 69 (2009), 2358–2364.
58. 58 Metz, S., et al. Bispecific digoxigenin-binding antibodies for targeted payload delivery. Proc. Natl. Acad. Sci. U.S.A. 108 (2011), 8194–8199.
59. 59 Mehrabadi, F., et al. Bispecific antibodies for targeted delivery of dendritic polyglycerol (dPG) prodrug conjugates. Curr. Cancer Drug. Targets 16 (2016), 639–649.
60. 60 Miller, K., et al. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. BMC Cancer, 16, 2016, 352.
61. 61 Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12 (2012), 252–264.
62. 62 Lee, L., et al. Immune checkpoint inhibitors: an introduction to the next-generation cancer immunotherapy. J. Clin. Pharmacol. 56 (2016), 157–169.
63. 63 Page, D.B., et al. Immune modulation in cancer with antibodies. Annu. Rev. Med. 65 (2014), 185–202.
64. 64 Sharon, E., et al. Immune checkpoint inhibitors in clinical trials. Chin. J. Cancer 33 (2014), 434–444.
65. 65 Kyi, C., Postow, M.A., Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett. 588 (2014), 368–376.
66. 66 Shih, K., et al. Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 74 (2014), 1993–2013.
67. 67 Baksh, K., Weber, J., Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations. Semin. Oncol. 42 (2015), 363–377.
68. 68 Webster, R.M., The immune checkpoint inhibitors: where are we now?. Nat. Rev. Drug Discov. 13 (2014), 883–884.
69. 69 Hodi, F.S., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363 (2010), 711–723.
70. 70 Dong, H., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8 (2002), 793–800.
71. 71 Keir, M.E., et al. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26 (2008), 677–704.
72. 72 Zheng, H., et al. Expression of PD-1 on CD4 + T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer. Oncotarget 7 (2016), 56233–56240.
73. 73 Khoja, L., et al. Pembrolizumab. J. Immunother. Cancer, 3, 2015, 36.
74. 74 Topalian, S.L., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32 (2014), 1020–1030.
75. 75 Cooper, A.J., et al. Immune checkpoint inhibitors in melanoma. Melanoma Manag. 2 (2015), 267–284.
76. 76 Ott, P.A., et al. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin. Cancer Res. 19 (2013), 5300–5309.
77. 77 Pandha, H., Pawelec, G., Immune checkpoint targeting as anti-cancer immunotherapy: promises, questions, challenges and the need for predictive biomarkers at ASCO 2015. Cancer Immunol. Immunother. 64 (2015), 1071–1074.
78. 78 Das, R., et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J. Immunol. 194 (2015), 950–959.
79. 79 Gardai, S.J., et al. A sugar engineered non-fucosylated anti-CD40 antibody, SEA-CD40, with enhanced immune stimulatory activity alone and in combination with immune checkpoint inhibitors. J. Clin. Oncol., 33(Suppl.), 2015, 3074.
80. 80 Atkins, M.B., Sznol, M., Cancer immunotherapy: past progress and future directions. Semin. Oncol. 42 (2015), 518–522.
81. 81 Kong, Y-C., Flynn, J.C., Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1. Front. Immunol., 5, 2014, 206.
82. 82 Massari, F., et al. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. Cancer Treat. Rev. 41 (2015), 114–121.
83. 83 Patel, M.A., et al. Present and future of immune checkpoint blockade: monotherapy to adjuvant approaches. World J. Immunol. 5 (2015), 1–15.
84. 84 Teng, F., et al. Radiotherapy combined with immune checkpoint blockade immunotherapy: achievements and challenges. Cancer Lett. 365 (2015), 23–29.
85. 85 Pilones, K.A., et al. Combination of radiotherapy and immune checkpoint inhibitors. Semin. Radiat. Oncol. 25 (2015), 28–33.
86. 86 Adams, S., et al. Istiratumab (MM-141), a bispecific antibody co-targeting IGF-1R and ErbB3, potentiates the activity of immune checkpoint inhibitors. Mol. Cancer Ther., 14, 2015, A89.
87. 87 Osada, T., et al. CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. Cancer Immunol. Immunother. 64 (2015), 677–688.
88. 88 Johnson, Z., et al. Bispecific antibody targeting of CD47/CD19 to promote enhanced phagocytosis of patient B lymphoma cells. J. Clin. Oncol., 33(Suppl.), 2015, e14016.
89. 89 Fitzgerald, J.B., et al. MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol. Cancer Ther. 13 (2014), 410–425.
90. 90 Beck, A., et al. Strategies and challenges for the next generation of therapeutic antibodies. Nat. Rev. Immunol. 10 (2010), 345–352.
91. 91 Pillay, V., et al. Antibodies in oncology. Nat. Biotechnol. 28 (2011), 518–529.
92. 92 Pedersen, M.W., et al. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res. 70 (2010), 588–597.
93. 93 Mathews Griner, L.A., et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc. Natl. Acad. Sci. U.S.A. 111 (2014), 2349–2354.
94. 94 Riedl, T., et al. High-throughput screening for internalizing antibodies by homogeneous fluorescence imaging of a pH-activated probe. J. Biomol. Screen. 21 (2016), 12–23.